Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galux-IL-18-antibody is an AI-designed monoclonal antibody targeting Interleukin-18 (IL-18), developed by Galux using its proprietary AI protein design platform, GaluxDesign. IL-18 is a pro-inflammatory cytokine belonging to the IL-1 family, which plays a significant role in the pathogenesis of various autoimmune and inflammatory diseases. This antibody is presented as a technology demonstration case of Galux's capability to design de novo proteins and antibodies with high specificity and affinity using computational methods. While IL-18 is explicitly listed as a target on the company's platform demonstration page, it has not yet been disclosed as a formal clinical candidate with a specific code name or assigned to a particular clinical development phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Galux-IL-18-antibody (AI-designed).